Net Debt Down to 2.35 TimesNarrow moat

Philip Morris International (PM) — moat facet

PMI has cut its leverage from 2.66 to 2.35 times EBITDA without cutting its debt, by growing into it.

PMI borrowed heavily to buy Swedish Match and is paying it down slowly. Total debt was $47.9 billion at the end of 20231, $45,695 million at the end of 2024 and $48,835 million at the end of 20252. Net debt was $41,479 million and $43,963 million at those two year ends3, and $43,114 million at 30 June 20264.

Net debt to adjusted EBITDA (x)2.66End-20242.53End-20252.35Jun 20262.0 targetTarget end-2026PMI Q4 2025 and Q2 2026 non-GAAP schedules; Q2 2026 release
Falling toward the target by growth.

Leverage measured against earnings is falling faster than the debt, because earnings are rising. Net debt was 2.66 times adjusted EBITDA at the end of 2024, 2.53 times at the end of 20255 and 2.35 times at 30 June 20266. PMI's target is "close to 2.0x by the end of 2026"7.

The rating agencies have noticed. Moody's revised PMI's outlook from stable to positive on 14 April 20268. And on 29 June 2026 PMI prepaid €1.0 billion, about $1.1 billion, of a euro term loan, leaving €1.5 billion due in June 20279.

The debt is serviceable. Net interest expense was $966 million in 202510, about 6.5% of operating income11. What it does is limit choice: with the target not yet reached, PMI plans no share repurchases12.

Liquidity improved alongside. Cash rose from $4,872 million at the end of 202513 to $5,999 million at 30 June 202614, even after the dividend, which is what allowed the early repayment of the euro term loan.

A balance sheet this leveraged is not a moat, but a steadily falling ratio shows the cash flow behind the moat is real. Net debt to adjusted EBITDA settles the question; the company's own target of about 2.0 times at the end of 2026 is the test, and a ratio still above 2.3 then would mean deleveraging has stalled.

Moat trajectory: Widening

Net debt/adjusted EBITDA 2.53x to 2.35x in six months; Moody's outlook positive.

The number that tests this moat
Reported
Net debt, latest quarter
$43,114M (30 June 2026), from $43,963M

The absolute debt behind the ratio; a rise while the ratio falls would mean earnings, not repayment, are doing the work.

Source: PMI Q2 2026 non-GAAP schedules ↗
⚠ Threats to the moat
⚠ THREAT 01
A $52 Billion Derivatives Book
PMI runs a $52 billion book of derivatives to hedge its currencies and debt, larger than the debt itself.
References
  1. ReportedTotal debt was $47.9 billion at the end of 2023, $45,695 million at the end of 2024 and $48,835 million at the end of 2025.
    Philip Morris International Form 10-K for fiscal 2024 - total assets and stockholders' deficit for 2023, total debt at the end of 2023, the weighted-average financing cost, and the Vectura sale. — FY2024 · publ. February 2025 · source ↗
  2. ReportedTotal debt was $47.9 billion at the end of 2023, $45,695 million at the end of 2024 and $48,835 million at the end of 2025.
    Philip Morris International Q4 2025 exhibit 99.2 - total debt, net debt, adjusted EBITDA and net debt to adjusted EBITDA. — FY2025 · publ. 6 February 2026 · source ↗
  3. ReportedNet debt was $41,479 million and $43,963 million at those two year ends, and $43,114 million at 30 June 2026.
    Philip Morris International Q4 2025 exhibit 99.2 - total debt, net debt, adjusted EBITDA and net debt to adjusted EBITDA. — FY2025 · publ. 6 February 2026 · source ↗
  4. ReportedNet debt was $41,479 million and $43,963 million at those two year ends, and $43,114 million at 30 June 2026.
    Philip Morris International Q2 2026 exhibit 99.2 - non-GAAP schedules, operating cash flow and net debt to adjusted EBITDA. — Q2 2026 · publ. 22 July 2026 · source ↗
  5. ReportedNet debt was 2.66 times adjusted EBITDA at the end of 2024, 2.53 times at the end of 2025 and 2.35 times at 30 June 2026.
    Philip Morris International Q4 2025 exhibit 99.2 - total debt, net debt, adjusted EBITDA and net debt to adjusted EBITDA. — FY2025 · publ. 6 February 2026 · source ↗
  6. ReportedNet debt was 2.66 times adjusted EBITDA at the end of 2024, 2.53 times at the end of 2025 and 2.35 times at 30 June 2026.
    Philip Morris International Q2 2026 exhibit 99.2 - non-GAAP schedules, operating cash flow and net debt to adjusted EBITDA. — Q2 2026 · publ. 22 July 2026 · source ↗
  7. ReportedPMI's target is "close to 2.0x by the end of 2026".
    Philip Morris International second-quarter 2026 results release, Form 8-K exhibit 99.1 - volumes, shares, ZYN and 2026 guidance - results, margins, operating companies income, cash and 2026 guidance. — Q2 2026 · publ. 22 July 2026 · source ↗
  8. ReportedMoody's revised PMI's outlook from stable to positive on 14 April 2026.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  9. ReportedAnd on 29 June 2026 PMI prepaid €1.0 billion, about $1.1 billion, of a euro term loan, leaving €1.5 billion due in June 2027.
    Philip Morris International Form 8-K, 29 June 2026 - prepayment of a euro term-loan tranche. — June 2026 · publ. 29 June 2026 · source ↗
  10. ReportedNet interest expense was $966 million in 2025, about 6.5% of operating income.
    Philip Morris International Form 10-K for fiscal 2025 - financial statements and notes: income statement, excise, cash flow, debt, acquisitions and impairments. — FY2025 · publ. 6 February 2026 · source ↗
  11. Moat Explorer calcNet interest expense was $966 million in 2025, about 6.5% of operating income.
    Moat Explorer calculation from Philip Morris International's reported figures ($ millions unless stated). Excise and revenue 2025: 53,211 / 40,648 = 1.31 dollars of excise per dollar of net revenue; gross of excise 53,211 + 40,648 = 93,859, excise share 53,211 / 93,859 = 56.7%; excise growth 2023-2025 53,211 / 49,404 - 1 = 7.7% against net revenue growth 40,648 / 35,174 - 1 = 15.6%. Product mix 2025: smoke-free 16,854 / 40,648 = 41.5%; combustible 23,794 / 40,648 = 58.5%; smoke-free 2023 12,840 / 35,174 = 36.5%, 2024 14,660 / 37,878 = 38.7%; smoke-free growth 2023-2025 16,854 / 12,840 - 1 = 31.3%; smoke-free revenue 2016 733 to 2025 16,854 = 23 times. Segments 2025: International Smoke-Free 13,996 / 40,648 = 34.4%; International Combustibles 23,436 / 40,648 = 57.7%; U.S. 3,216 / 40,648 = 7.9%; recast gross profit shares 9,576 / 27,304 = 35.1%, 15,523 / 27,304 = 56.9%, 2,206 / 27,304 = 8.1%. Growth 2025: ISF 13,996 / 12,126 - 1 = 15.4%; IC 23,436 / 22,807 - 1 = 2.8%; U.S. 3,216 / 2,944 - 1 = 9.2%. Growth 2024: ISF 12,126 / 11,102 - 1 = 9.2%; IC 22,807 / 21,903 - 1 = 4.1%; U.S. 2,944 / 2,169 - 1 = 35.7%. IC gross profit 15,523 / 13,972 - 1 = 11.1% against IC revenue 23,436 / 21,903 - 1 = 7.0% (2023-2025). Recast reported gross margins 2023: ISF 7,021 / 11,102 = 63.2%, IC 13,972 / 21,903 = 63.8%; 2024: ISF 7,831 / 12,126 = 64.6%, IC 14,687 / 22,807 = 64.4%. Segment sum 2024 12,126 + 22,807 + 2,944 = 37,877 against 37,878 reported. IC shares of net revenues 21,903 / 35,174 = 62.3% (2023), 22,807 / 37,878 = 60.2% (2024). U.S. revenue 3,216 / 2,169 - 1 = 48.3% (2023-2025). Q2 2026 shares: ISF 3,877 / 11,192 = 34.6%, IC 6,459 / 11,192 = 57.7%, U.S. 856 / 11,192 = 7.6%. U.S. gross margin Q2 2026 555 / 856 = 64.8% against 611 / 862 = 70.9%. Swedish Match: 14,460 + 1,495 + 883 = 16,838 total cash paid; U.S. adjusted operating companies income 1,124 / 16,838 = 6.7% pre-tax; reported U.S. OCI 322 / 3,216 = 10.0% of U.S. revenue; adjusted 1,124 / 3,216 = 35.0%. Goodwill and other intangibles 17,264 + 10,884 = 28,148, 28,148 / 69,185 = 40.7% of total assets. Volumes: cigarettes 607,367 / 616,827 - 1 = -1.5% (2025), 607,367 / 612,949 - 1 = -0.9% (2023-2025); heated tobacco units 155,133 / 139,743 - 1 = 11.0% (2025), 139,743 / 125,263 - 1 = 11.6% (2024); HTUs 155,133 / (607,367 + 155,133) = 20.3% of cigarette plus HTU shipments. U.S. ZYN cans 793.7 / 384.8 = 2.06 times (2023-2025), 793.7 / 580.5 - 1 = 36.7% (2025); international nicotine pouches 879.6 - 793.7 = 85.9 million cans (2025), 644.0 - 580.5 = 63.5 (2024); snus 227.9 / 240.4 - 1 = -5.2% (2023-2025); e-vapor 3,330 / 1,651 = 2.0 times. U.S. segment: cigars 358 / 410 - 1 = -12.7%, 358 / 431 - 1 = -16.9% (2023-2025); wellness 238 / 333 - 1 = -28.5%. Cash and dividends: free cash flow 12,233 - 1,569 = 10,664 (2025), 12,217 - 1,444 = 10,773 (2024), 9,204 - 1,321 = 7,883 (2023); dividends paid / free cash flow 8,624 / 10,664 = 80.9% (2025), 8,197 / 10,773 = 76.1% (2024), 7,964 / 7,883 = 101.0% (2023). Payout of declared dividends per share over diluted EPS: 5.64 / 7.26 = 77.7% (2025), 5.30 / 4.52 = 117.3% (2024), 5.14 / 5.02 = 102.4% (2023); over adjusted EPS 5.64 / 7.54 = 74.8%. Annualised dividend 1.60 x 4 = 6.40; 6.40 / 5.64 = 1.13; dividend 5.64 / 1.54 = 3.7 times since 2008; yield 6.40 / 190.48 = 3.4%. R&D 756 / 40,648 = 1.9% of revenue; capex 1,569 / 40,648 = 3.9%. Customers: two customers 12% + 10% = 22% of 2025 net revenues; related-party revenue 4,582 / 40,648 = 11.3%; Megapolis 2,805 / 40,648 = 6.9%; Megapolis growth 2,805 / 2,393 - 1 = 17.2%. Japan 4.2 / 40.6 = 10.3% of net revenues. Canada: RBH carrying value 3,280 fair value at deconsolidation to 51 at 30 June 2026; impairments 2,316 + 511 = 2,827. Valuation: trailing twelve months to June 2026 revenue 40,648 + 21,338 - 19,441 = 42,545; net earnings 11,348 + 5,255 - 5,729 = 10,874; P/E 296.88 / 10.874 = 27.3; P/S 296.88 / 42.545 = 6.98; 2018 P/E 103.78 / 7.911 = 13.1; 2025 P/E 249.68 / 11.348 = 22.0; free cash flow yield 10,664 / 296,880 = 3.6%. Other PMI cigarette brands: 25.4 - 9.8 = 15.6% (2023), 25.3 - 10.7 = 14.6% (2025), a loss of 1.0 point against Marlboro's gain of 0.9. Excise Q2 2026 14,973 / 13,272 - 1 = 12.8% against net revenues 11,192 / 10,140 - 1 = 10.4%. U.S. smoke-free H1 1,584 - 1,311 = 273 decline. ISF H1 2026 gross margin 5,400 / 7,713 = 70.0%. Gross margin 2025 27,282 / 40,648 = 67.1%. ROIC average 2015-2025 (45.6 + 50.2 + 43.4 + 50.7 + 48.7 + 52.1 + 57.2 + 40.6 + 26.8 + 28.6 + 32.5) / 11 = 43.3%. Employees 84,900 - 82,700 = 2,200 (2023-2025); net revenues 40,648 - 35,174 = 5,474, about 5.5 billion. Snus 240.4 - 227.9 = 12.5 million cans. Europe smoke-free 8,127 / 16,854 = 48.2%, about half. Cigarette decline 2% to 3% of 607,367 = 12,147 to 18,221 million units. Operating cash flow over R&D 12,233 / 756 = 16.2 times. Blocked markets 440 / 2,587 = 17%, about a sixth. Market cap against peers 296.88 / 119.41 = 2.5 times British American Tobacco; 296.88 / 114.91 = 2.6 times Altria. Net debt to adjusted EBITDA 43,963 / 17,375 = 2.53. Interest 966 / 14,892 = 6.5% of operating income. Guidance midpoints: (8.35 + 8.50) / 2 = 8.43, reported (7.28 + 7.43) / 2 = 7.36, gap 8.43 - 7.36 = 1.07; earlier adjusted midpoints (8.38 + 8.53) / 2 = 8.46, (8.31 + 8.46) / 2 = 8.39, (8.26 + 8.41) / 2 = 8.34; 8.43 / 7.54 - 1 = 11.8% - cash flow, dividends, debt and valuation. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in PMI's Forms 10-K and 10-Q, the recast segment schedules, results releases and market data; operands shown in the source line.
  12. ReportedWhat it does is limit choice: with the target not yet reached, PMI plans no share repurchases.
    Philip Morris International second-quarter 2026 results release, Form 8-K exhibit 99.1 - volumes, shares, ZYN and 2026 guidance - results, margins, operating companies income, cash and 2026 guidance. — Q2 2026 · publ. 22 July 2026 · source ↗
  13. ReportedCash rose from $4,872 million at the end of 2025 to $5,999 million at 30 June 2026, even after the dividend, which is what allowed the early repayment of the euro term loan.
    Philip Morris International Form 10-K for fiscal 2025 - financial statements and notes: income statement, excise, cash flow, debt, acquisitions and impairments. — FY2025 · publ. 6 February 2026 · source ↗
  14. ReportedCash rose from $4,872 million at the end of 2025 to $5,999 million at 30 June 2026, even after the dividend, which is what allowed the early repayment of the euro term loan.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
Sources
Generated September 26, 2026